1. Шамшева О.В. и др. Парентеральные вирусные гепатиты у детей: учебное пособие [для студентов медицинских вузов]. Москва: РНИМУ им. Н.И. Пирогова, 2021. 108 p. 2. Лобзин Ю.В. и др. Вирусные гепатиты. СПб: ФОЛИАНТ, 2011. 304 с. 3. Справочник по инфекционным болезням у детей / ed. Лобзин Ю.В. СанктПетербург: СпецЛит, 2013. 591 с. 4. National Clinical Guideline Centre (UK). Hepatitis B (Chronic): Diagnosis and Management of Chronic Hepatitis B in Children, Young People and Adults. London: National Institute for Health and Care Excellence (UK); 2013 Jun. PMID: 25473721 5. Инфекционные болезни. Национальное руководство. 3-е издание, переработанное и дополненное / ed. Ющук Н.Д., Венгеров Ю.Я. Москва: ГЭОТАР-Медиа, 2021. 1104 с. 6. Ющук Н.Д., Знойко О.О., Белый П.А. Вирусные гепатиты. Клиника, диагностика, лечение. Библиотека врача-специалиста / ed. Ющук Н.Д. Москва: ГЭОТАР-Медиа, 2018. 368 с. 7. Покровский В.И. и др. Инфекционные болезни и эпидемиология: учебник— 3-е изд., испр. и доп. Москва: ГЭОТАР-Медиа, 2018. 1008 p. 8. Кузнецов Н.И. Вирусный гепатит В // Российский семейный врач. 2012. Т. 16, № 4. С. 13–18. 9. Trépo C., Chan H.L.Y., Lok A. Hepatitis B virus infection // The Lancet. Lancet Publishing Group, 2014. Vol. 384, № 9959. P. 2053–2063. 10. Tong S., Revill P. Overview of hepatitis B viral replication and genetic variability // J. Hepatol. 2016. P. 1–26. 11. Костюшев Д.С. и др. Роль ДНК-метилтрансфераз в жизненном цикле вируса гепатита B и патогенезе хронического гепатита B. // Вопросы вирусологии. 2018. Т. 63, № 1. С. 19–29. 12. Волынец Г.В., Панфилова В.Н. Хронический вирусный гепатит В у детей и подростков: современный взгляд на проблему // Российский вестник перинатологии и педиатрии. 2020. Т. 65, № 4. С. 47–60. 13. Seeger C., Mason W.S. Molecular biology of hepatitis B virus infection // Virology. Academic Press Inc., 2015. Vol. 479–480. P. 672–686 14. Tian Y. et al. Hepatitis B Virus X Protein-Induced Aberrant Epigenetic Modifications Contributing to Human Hepatocellular Carcinoma Pathogenesis // Mol. Cell. Biol. 2013. Vol. 33, № 15. P. 2810–2816. 15. Kim S. et al. Hepatitis B virus X protein activates the ATM-Chk2 pathway and delays cell cycle progression // ournal Gen. Virol. 2015. Vol. 96. P. 2242–2251. 16. Zhu M. et al. Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells // Oncotarget. Vol. 6, № 14. 12196– 12208 p. 76 17. Sunbul M. Hepatitis B virus genotypes: Global distribution and clinical importance // World J. Gastroenterol. 2014. Vol. 20, № 18. P. 5427–5434. 18. Maini M.K., Gehring A.J. The role of innate immunity in the immunopathology and treatment of HBV infection // Journal of Hepatology. Elsevier B.V., 2016. Vol. 64, № 1. P. S60–S70. 19. Cao L.-H. et al. Effect of hepatitis B vaccination in hepatitis B surface antibody-negative pregnant mothers on the vertical transmission of hepatitis B virus from father to infant. // Exp. Ther. Med. 2015. Vol. 10, № 1. P. 279–284. 20. Liu J. et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: A community-based follow-up study // Gastroenterology. W.B. Saunders, 2010. Vol. 139, № 2. P. 474–482. 21. Bertoletti A., Ferrari C. Adaptive immunity in HBV infection // J. Hepatol. Elsevier B.V., 2016. Vol. 64, № 1. P. 71–83. 22. Brunetto M.R. et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers // Gastroenterology. W.B. Saunders, 2010. Vol. 139, № 2. P. 483–490. 23. Shi W, Zhang Z, Ling C, Zheng W, Zhu C, Carr MJ, Higgins DG. Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections. Infect Genet Evol. 2013 Jun;16:355-61. doi: 10.1016/j.meegid.2013.03.021. Epub 2013 Mar 26. PMID: 23538336.] 24. Santantonio T, Fasano M. Current concepts on management of chronic hepatitis B. In: Serviddio G, editor. Practical management of chronic viral hepatitis [Internet]. InTech; 2013 Available from: http://www.intechopen.com/books/practical-managementofchronic-viral-hepatitis/current-concepts-on-management-of-chronic-hepatitis-b (accessed: 19.06.2021). 25. Чуланов, Владимир Петрович. Эпидемиологическое и клиническое значение генетической гетерогенности вирусов гепатита А и В : диссертация ... доктора медицинских наук : 14.02.02 / Чуланов Владимир Петрович; [Место защиты: ГОУВПО "Российский университет дружбы народов"].- Москва, 2013.- 276 с.: ил. 26. Ni Y. et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes // Gastroenterology. 2014. Vol. 146, № 4. P. 1070–1083 27. Lucifora J., Protzer U. Attacking hepatitis B virus cccDNA – The holy grail to hepatitis B cure // J. Hepatol. European Association for the Study of the Liver, 2016. Vol. 64, № 1. P. S41–S48. 28. Allweiss L. et al. The Role of cccDNA in HBV Maintenance. 29. Diogo Dias J. et al. Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation. 2021. 30. Wei L., Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand // Nat. Commun. 2021. Vol. 12, № 1591. P. 1–13. 31. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection | Elsevier Enhanced Reader [Electronic resource]. URL: https://reader.elsevier.com/reader/sd/pii/S016882781730185X?token=996B34855DDD7 0609EE7ADCF455D71735A969FF633F937EFF23051F7A4C119D59EE8800F7057DC 95F9265AE3DF0D13FC&originRegion=eu-west-1&originCreation=20210617135011 (accessed: 17.06.2021). 32. Goh Z.Y. et al. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B Conflict-of-interest statement // World J Gastroenterol. 2021. Vol. 27, № 14. P. 1369–1391. 33. Van Damme P. Hepatitis B Vaccines // Vaccines. 6th Edition / ed. Plotkin S., Orenstein W., Offit P. Elsevier Sanders, 2017. P. 1570. 77 34. Shimakawa Y. et al. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: A case-control study in The Gambia // Liver Int. Blackwell Publishing Ltd, 2015. Vol. 35, № 10. P. 2318–2326. 35. Talla C. et al. Hepatitis B infection and risk factors among pregnant women and their male partners in the Baby Shower Programme in Nigeria: a cross-sectional study // Trop. Med. Int. Heal. Blackwell Publishing Ltd, 2021. Vol. 26, № 3. P. 316–326. 36. Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: A review // Clin. Infect. Dis. Oxford Academic, 1995. Vol. 20, № 4. P. 992–1000. 37. Kim Y.J. et al. A genome-wide association study identified new variants associated with the risk of chronic hepatitis B 38. Li Y. et al. Genome-wide association study identifies 8p21.3 associated with persistent hepatitis B virus infection among Chinese // Nat. Commun. 2016. Vol. 7. 39. WHO. GLOBAL HEPATITIS REPORT, 2017 [Electronic resource]. 2017. URL: https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455- eng.pdf?sequence=1&isAllowed=y (accessed: 19.06.2021). 40. Eke A.C. et al. Hepatitis B immunoglobulin during pregnancy for prevention of motherto-child transmission of hepatitis B virus // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2017. Vol. 2017, № 2. 41. World Health Organization. Гепатит В. Информационный бюллетень ВОЗ [Electronic resource]. 2020. № July. P. 1–8. URL: http://www.who.int/mediacentre/factsheets/fs204/en. (accessed: 19.06.2021). 42. Михайлов М.И. и др. Проект программы по контролю и ликвидации вирусных гепатитов как проблемы общественного здоровья в Российской Федерации // Инфекционные болезни: новости, мнения, обучение. 2018. Т. 7, № 2. С. 52–58. 43. Шилова И.В. и др. Успехи и проблемы профилактики гепатита В у детей. Новые пути решения. 2019. Т. 21, № 3. С. 403–409 44. Ip H.M.H. et al. Prevention of hepatitits B virus carrier state in infants according to maternal serum levels of HBV DNA // Lancet. 1989. Vol. 333, № 8635. P. 406–410. 45. Technical Report. Interim guidance for country validation of viral hepatitis elimination. 2021. № June. 1–96 p. 46. Indolfi G, et. al Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-476. doi: 10.1016/S2468-1253(19)30042-1. Epub 2019 Apr 11. Erratum in: Lancet Gastroenterol Hepatol. 2020 May;5(5):e4. PMID: 30982722. 46. 47. Awad ME-D, Shiha GE, Sallam FA, Mohamed A, El Tawab A. Evaluation of liver stiffness measurement by fibroscan as compared to liver biopsy for assessment of hepatic fibrosis in children with chronic hepatitis C. J Egypt Soc Parasitol 2013; 43: 805–19 48. .Sokal EM, Paganelli M, Wirth S, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 2013; 59: 814–29. 47. 49. Chen YC, Chu CM, Liaw YF. Age-specifi c prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435–44 50. Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013; 58: 853–60. 51. Wu JF, Su YR, Chen CH, et al. Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children. J Pediatr Gastroenterol Nutr 2012; 54: 97–100 78 52.48. Mason W.S., Gill U.S., Litwin S., Zhou Y., Peri S., Pop O. et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterol 2016;151:986–998. DOI: 10.1053/j.gastro.2016.07.012 53.49. Cornberg M., Wong V.W., Locarnini S., Brunetto M., Janssen H.L., Chan H.L. The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017; 66(2): 398–411. DOI: 10.1016/j.jhep.2016.08.009 54. Esaulenko E.V., Shibaeva E.O., frequency and the clinical significance of occult hepatitis b virus infection, Инфекция и иммунитет, 2018, 714 55. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652–7 56.50. Тимченко В.Н., Анненкова И.Д., Бабаченко И.В. Инфекционные болезни у детей / ed. Тимченко В.Н. СПб: СпецЛит, 2012. 623 с. 57.51. Учайкин В.Ф., Чередниченко Т.В., Смирнов А.В. Инфекционная гепатология. Руководство для врачей. Москва: ГЭОТАР-Медиа, 2014. 608 с. 58.52. World Health Organization. Global policy report on the prevention and control of viral hepatitis in WHO member states [Internet]. Geneva: World Health Organization; 2013. Available from: http://www.who.int/hiv/pub/hepatitis/global_report/en 59.53. Аутоиммунный гепатит и его вариантные формы: новый взгляд и новые возможности лечения: пособие для врачей / Т.Н. Лопаткина; Клиника нефрологии, внутр.и проф. болезней им. Е.М. Тареева, Первый МГМУ им. И.М. Сеченова. – М: Форте принт, 2014. – 36 с. 60.54. Волынец Г.В., Хавкин А.И., Скворцова Т.А., Маткаш В.В. Аутоиммунный гепатит у детей: современное состояние проблемы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018; Т. 28 №5 С. 18–34. https://doi.org/10.22416/1382-4376-2018-28-5-18-34 61.55. European Association for the Study of the L. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol. 2015;63:971–1004. 62.56. Лекарственные поражения печени: учеб.пособие для врачей/ Хомерики С.В., Хомерики Н.М. – М.: ФортеПринт, 2012. – 40 с. 63.57. EASL Clinical Practice Guidelines: Drug-induced liver injuryq European Association for the Study of the Liver Journal of Hepatology 2019 vol. 70 j 1222–1261 64.58. Sturm E., Piersma F.E., Tanner M.S., Socha P., Roberts E.A., Shneider B.L. Controversies and Variation in Diagnosing and Treating Children With Wilson Disease: Results of an International Survey. J Pediatr Gastroenterol Nutr. 2016; 63 (1): 82 - 7. 65.59. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson"s disease. J Hepatol. 2012; 56 (3): 671 - 85. 66.60. American Thoracic / European Respiratory Society statement: standards for the diagnosis and management of individuals with alpfa-1antitrypsin deficiency. Am J Respire Crit Care med 2003;168:818-900. 67.61. Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, Siberry G, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):477-487. doi: 10.1016/S2468-1253(19)30046-9. Epub 2019 Apr 11. Erratum in: Lancet Gastroenterol Hepatol. 2020 May;5(5):e4. PMID: 30982721 68.62. El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol. 2019 Sep;20(3):163-174. doi: 10.1016/j.ajg.2019.09.003. Epub 2019 Oct 1. PMID: 31585703 69.63. Pawlowska M, Sobolewska-Pilarczyk M, Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral. World J Gastroenterol. 2018;24(24):2555-2566. doi:10.3748/wjg.v24.i24.2555 79 70.64. Эсауленко Е. В., Алексеева М. В., Сухорук А. А., Понятишина М. В., Прийма Е. Н., Бубочкин А. Б. Фульминантный гепатит в реальной клинической практике, Инфекционные болезни 2017, С. 70-74. 71.65. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57:442–50. 72. Cardona NE, Loureiro CL, Garzaro DJ, Duarte MC, García DM, Pacheco MC, et al. Unusual presentation of hepatitis B serological markers in an Amerindian community of Venezuela with a majority of occult cases. Virol J 2011; 8:527. 73.66. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335–52. 74.67. Hepatitis B Foundation. Hepatitis B Foundation [Internet]. Doylestown, PA. Available from: http://www.hepb.org/ 75.68. Сухорук А. А, Захаров К.А., Шиманская А.С., Стасишкис Т. А., Эсауленко Е. В., Ковеленов А. Ю. Анализ результатов долгосрочной этиотропной терапии HBeAg-негативного хронического гепатита В. Инфекционные болезни: новости, мнения, обучение 2019, С. 34-39. 76.69. Чередниченко Т.В., Московская И.А. Вирусные гепатиты у детей первого года жизни // Детские Инфекции. 2003. Т. 3. С. 11–14. 77.70. Terrault, N.A., Lok, A.S., McMahon, B.J., Chang, K.-M., Hwang, J.P., Jonas, M.M., Brown, R.S., Jr., Bzowej, N.H. and Wong, J.B. (2018), Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 67: 1560-1599. https://doi.org/10.1002/hep.29800 78.71. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1-98. doi:10.1007/s12072-015-9675-4 79.72. Медицинское пособие "Диагностика и лечение хронических гепатитов у детей /Горячева Л.Г., Рогозина Н.В., Шилова И.В., Карев В.Е., Грешнякова В.А./Научные труды,Ю Т.7 "Современные подходы к диагностике, терапии и профилактике инфекционных заболеваний у детей (псвящается 90-летию со дня основания института)"/ Под. ред.з.д.н. РФ акад. РАН, д.м.н.проф. Лобзина Ю.В., з.д.н.РФ, проф.Скрипченко Н.В. - СПб.: НИИДИ, 2017 С.180-224. 80.73. Interferon alfa-2b therapy in children with chronic hepatitis В / Sokal E. М. et all. // Gut. — 1993. — V. 34. (2 suppi). — P. 587 — 590. 81. Строкова Т. В. Ламивудин в терапии хронического гепатита В у детей / Т. В. Строкова, Л. В. Чистова, А. И. Потапов — Сб. тез. VII Конгресса педиатров России. — М., 2002. — С. 296. 82. Рейзис А. Р. Новое в противовирусной терапии хронического гепатита В у детей / А. Р. Рейзис, Е. А. Нурмухаметова, О. Ю. Шипулина // Эпидимиол и инф б – ни. – 2001. - №4. – С. 28 – 31. 83. Пономарева М.А., Шилова И.В., Горячева Л.Г. Применение ламивудина при хроническом гепатите В у детей.Детские инф., 2004.-№1. – С.30-33. 84. Long – term efficacy of interferon alpha – 2b and lamivudine in combination compared to lamivudine monotherapy, randomized trial. / Barbaro G. et al // J. Hepatol. – 2001. – V. 35. – P. 406 – 411 85.74. .Reversion from precore/core promoter mutants to wild – type hepatits B virus during the course of lamivudin therapy / Cho S. W. et al. // Ibid. – 2000. – V. 32. – P. 1163 – 1169 86. Горячева Л.Г. et al. Неонатальные гепатиты: прогноз течения и тактика ведения. Методическое пособие // Современные подходы к диагностике, терапии и профилактике инфекционных заболеваний у детей. СПб: Тактик-Студио, 2013. С. 531–548. 80 87. Циклоферон® (Cycloferon®), инструкция, способ применения и дозы, побочные действия, отзывы о препарате, рАСТвор для внутривенного и внутримышечного введения, 125 мг/мл, таблетки, покрытые кишечнорАСТворимой оболочкой, 150 мг, линимент, 5% — Энциклопедия лекарств РЛС [Electronic resource]. URL: https://www.rlsnet.ru/tn_index_id_5723.htm (accessed: 22.06.2021). 88.75. Еналеева Д.Ш., Фазылов В.Х., Созинов А.С. Хронические вирусные гепатиты В, С и D. Руководство для врачей. Москва: ГЭОТАР-Меди, 2015. 194 с. 89.76. Крамарь Л.В. Особенности лечения вирусных гепатитов у детей // Лекарственный Вестник. 2018. Т. 4. - № 72. - С. 34–40. 90.77. National Institute for Health and Care Excellence (NICE). Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults [Internet]. London: NICE; 2013. Available from: http://www.nice.org.uk/guidance/cg165/resources/guidance-hepatitis-b-chronic-pdf 78. . Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095– 128. 91.79. Постановление Главного государственного санитарного врача РФ от 28.02.2008 N 14 “Об утверждении санитарно-эпидемиологических правил СП 3.1.1.2341-08” (вместе с "СП 3.1.1.2341-08. Профилактика вирусного гепатита B. Санитарно-эпидемиологические / КонсультантПлюс [Electronic resource]. URL: http://www.consultant.ru/document/cons_doc_LAW_75983/ (accessed: 22.06.2021). 92. Постановление Главного государственного санитарного врача РФ от 28.02.2008 N 14 “Об утверждении санитарно-эпидемиологических правил СП 3.1.1.2341-08” (вместе с "СП 3.1.1.2341-08. Профилактика вирусного гепатита B. Санитарноэпидемиологические / КонсультантПлюс [Electronic resource]. URL: http://www.consultant.ru/document/cons_doc_LAW_75983/ (accessed: 22.06.2021). 93.80. WHO. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy // Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. 2020. № July. 1–58 p. 94.81. Hu Y., Yu H. Prevention strategies of mother-to-child transmission of hepatitis B virus (HBV) infection. // Pediatr. Investig. Blackwell Publishing Ltd, 2020. Vol. 4, № 2. P. 133–137 95.82. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661–2. 96.83. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6:531–61. 97.84. World Health Organization. Global Alert and Response (GAR): Hepatitis [Internet]. Geneva: World Health Organization [cited 2015 Mar 31]. Available from: http://www.who.int/csr/disease/hepatitis/en/. 98.85. Pujol FH, Navas MC, Hainaut P, Chemin I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett 2009; 286:80–8. 99.86. Yousif M, Mudawi H, Bakhiet S, Glebe D, Kramvis A. Molecular characterization of hepatitis B virus in liver disease patients and asymptomatic carriers of the virus in Sudan. BMC InfectDis 2013; 13:328. 100.87. Ahmed CS, Wang Z, Bin Z, Chen J, Kamal M, Hou J. Hepatitis B virus genotypes, subgenotypes, precore, and basal core promoter mutations in the two largest provinces of Pakistan. J Gastroenterol Hepatol 2009; 24:569–73. 81 101.88. Эсауленко Е. В., Цинзерлинг В. А., Карев В. Е., Шибаева Е. О., Оккультный хронический гепатит В: клинико-морфологические сопоставления, Вестник новгородского государственного университета им. Ярослава Мудрого, 2016, 80-84 102. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol BiomarkPrev 2012; 21:793–9. 103. Строкова Т.В. Павловская Е.В., Зубович А.И., Каганов Б.С.Лечебное питание при заболеваниях печени у детей. Вопросы практической педиатрии, 2009, т.4, №1, с.66-71 89. 90. Huang J. F. et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? //Journal of internal medicine. – 2006. – Т. 260. – №. 3. – С. 255-262. Maggiore G. Сhronic hepatitis B in children: a retrospective multicenter study in Italy. Pediatr Res 20, 699 (1986). https://doi.org/10.1203/00006450-198607000-00083 91. B.A. Haber, J.M. Block, M.M. Jonas, S.J. Karpen, W.T. London, B.J. McMahon, et al. Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B Pediatrics, 124 (2009), pp. e1007-e1013 92. Raffaele Iorio, Antonietta Giannattasio, Francesco Cirillo, Luca D'Alessandro, Angela Vegnente, Long-Term Outcome in Children with Chronic Hepatitis B: A 24-Year Observation Period, Clinical Infectious Diseases, Volume 45, Issue 8, 15 October 2007, Pages 943–949, https://doi.org/10.1086/521864 93. Волынец Г.В., Панфилова B.H., Жаворонок C.B. Хронические вирусные гепатиты у детей. Учебное пособие. - М.: Издательский Дом ТОНЧУ, 2020. - 376 с. Clinical value of prothrombin time and hepatic thromboplastin test in the diagnosis of hepatic fibrosis staging of chronic hepatitis B virus / 中国基层医药Ying QIN. Chinese Journal of Primary Medicine and Pharmacy ; (12): 1472-1475, 2019. Teloh HA. Serum proteins in hepatic disease. Ann Clin Lab Sci. 1978 Mar-Apr;8(2):127- 9. PMID: 637517 94. Shah U, Kelly D, Chang MH, et al. Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr 2009; 48:399 95. Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a metaanalysis. Clin Infect Dis 1996; 23:131. 96. Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, et al. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PloS One 2013;8:e58071. 97. Jolynne Mokaya, Anna L McNaughton, Martin J Hadley, Apostolos Beloukas, AnnaMaria Geretti, Dominique Goedhals, Philippa C Matthews A systematic review of Hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: a call for urgent action. bioRxiv 258350; doi: https://doi.org/10.1101/258350 98. Luo A, Jiang X, Ren H. Virol J.Lamivudine therapy for chronic hepatitis B in children: a meta-analysis. 2019 Jul 4;16(1):88. doi: 10.1186/s12985-019-1193-x. 104. Jonas et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. Hepatology. 2016 Jan;63(1):307-18. doi: 10.1002/hep.28278. Epub 2015 Nov 13. PMID: 26566163. 99. Современные подходы к диагностике, терапии и профилактике инфекционных заболеваний у детей: научные труды: Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства России: Санкт-Петербург: Т. 10, 2020. 82 100. Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996; 15:223. 101. Murray KF, Szenborn L, Wysocki J, Rossi S, Corsa AC, Dinh P, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012;56:2018-2026. 102. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM; International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002 May 30;346(22):1706-13. doi: 10.1056/NEJMoa012452. Erratum in: N Engl J Med 2002 Sep 19;347(12):955. Kelley, Deirdre [corrected to Kelly, Deirdre]. PMID: 12037150 103. Строкова Т.В. Павловская Е.В., Зубович А.И., Каганов Б.С.Лечебное питание при заболеваниях печени у детей. Вопросы практической педиатрии, 2009, т.4, №1, с.66-71 Lee, Kyung Jae et al. “A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)idenaïve Chronic Hepatitis B.” Journal of Korean medical science vol. 33,8 e63. 19 Feb. 2018, doi:10.3346/jkms.2018.33.e63 Simko V, Michael S, Prego V. Ursodeoxycholic therapy in chronic liver disease: a metaanalysis in primary biliary cirrhosis and in chronic hepatitis. Am J Gastroenterol. 1994; 89: 392–398. Lirussi F, Beccarello A, Bortolato L, et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver 1999; 19: 381–388. 20. Puoti C, Magrini A, Filippi T, et al. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur J Gastroenterol Hepatol 1995; 7: 151–154. Bellentani S, Podda M, Tiribelli C, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol 1993; 19: 459–464. Podda M, Ghezzi C, Battezzati PM, et al. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. Gastroenterology 1990; 98: 1044– 1050. 23. Crosignani A, Battezzati PM, Setchell KD, et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a doseresponse study. Hepatology 1991; 13: 339–344 Cadranel, et al. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placeborandomized study. Transplantation, (2003), 977– 982. doi:10.1097/01.tp.0000055831.63841.b6 104. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Федосьина Е.А., Бессонова Е.Н., Пирогова, И.Ю., Гарбузенко Д.В. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102 105. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis //J hepatol. – 2018. – Т. 69. – №. 2. – С. 406-460. 106. Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S, Marra F, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993;13:156–62 107. Filippo Morando 1, Silvia Rosi, Elisabetta Gola, Mariateresa Nardi, Salvatore Piano, Silvano Fasolato, Marialuisa Stanco, Marta Cavallin, Antonietta Romano, 83 Antonietta Sticca, Lorenza Caregaro, Angelo Gatta, Paolo Angeli/ Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life crosssectional study 108. Morando F, Rosi S, Gola E, Nardi M, Piano S, Fasolato S, Stanco M, Cavallin M, Romano A, Sticca A, Caregaro L, Gatta A, Angeli P. Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. Liver Int. 2015 May;35(5):1508-15. doi: 10.1111/liv.12583. Epub 2014 May 21. PMID: 24811138. 109. Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986;90:1827– 1833. 110. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liver Dis 1994;14:23–34. 111. Bernardi M, Servadei D, Trevisani F, Rusticali AG, Gasbarrini G. Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 1985;31:189–193. 112. Santos J. et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety //Journal of hepatology. – 2003. – Т. 39. – №. 2. – С. 187-192 Dong Wu, Shu-Mei Wu, Jie Lu, Ying-Qun Zhou, Ling Xu, Chuan-Yong Guo, "Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A MetaAnalysis", Gastroenterology Research and Practice, vol. 2013, Article ID 236963, 9 pages, 2013 El-Karaksy, H.M., Afifi, O., Bakry, A. et al. A pilot study using lactulose in management of minimal hepatic encephalopathy in children with extrahepatic portal vein obstruction. World J Pediatr 13, 70–75 (2017). https://doi.org/10.1007/s12519-016- 0066-2 105. Sharma P, Sharma BC. Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose. Saudi J Gastroenterol. 2011;17(2):138-141. doi:10.4103/1319-3767.77246 106. Caraceni P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018 Jun 16;391(10138):2417- 2429. doi: 10.1016/S0140-6736(18)30840-7. Epub 2018 Jun 1. Erratum in: Lancet. 2018 Aug 4;392(10145):386. PMID: 29861076. 2 Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, et al. Long-term albumin administration in decompensated cirrhosis: an open label randomized trial. Lancet 2018, [In press]. Sola E, Sola C, Simon-Talero M, Martin-Llahi M, Castellote J, GarciaMartinez R, et al. Midodrine and albumin for prevention of complications of cirrhosis in patients in the waiting list for liver transplantation. A randomized, multicenter, double-blind, placebocontrolled trial. J Hepatol 2017;66:S11. 107. Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology. 2021 Sep;74(3):1660-1673. doi: 10.1002/hep.31708. Epub 2021 Jun 7. PMID: 33421158; PMCID: PMC8518409. 84 113. Гасилина Е.С., Борисова О.В., Санталова Г.В.. Роль инфекций в формировании хронической болезни почек у детей // Практическая медицина. 2012. 1(56). С. 7–12. 114. El-Sayed R. et al. Assessment of coagulation and fibrinolysis in children with chronic liver disease //Blood Coagulation & Fibrinolysis. – 2013. – Т. 24. – №. 2. – С. 113-117. 115. Клинический протокол диагностики и лечения хронического вирусного гепатита В у детеетй от 10 сентября 2015г. Протокол 10 116. Bortolotti F. et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29‐year longitudinal study //Hepatology. – 2006. – Т. 43. – №. 3. – С. 556-562. 117. Winther T. N. et al. Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B //PloS one. – 2013. – Т. 8. – №. 3. – С. e58236. 118. Bortolotti F. et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period //Journal of hepatology. – 1998. – Т. 29. – №. 2. – С. 184- 190. 119. Hsu H. C. et al. Pathology of chronic hepatitis B virus infection in children: with special reference to the intrahepatic expression of hepatitis B virus antigens //Hepatology. – 1988. – Т. 8. – №. 2. – С. 378-382. 120. Lebensztejn D. M. et al. Thyroid function in children with diagnosed chronic hepatitis B treated with interferon alpha //Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego. – 2000. – Т. 8. – №. 48. – С. 378-380. Рейзис А.Р., Матанина Н.В., Шмаров Д.А.. Антиапоптическое действие урсодезоксихолевой кислоты // Инфекционные болезни. 2006. Т4. №2. С. 1–9 121. Пономарева М.А, Шилова И.В., Рогозина Н.В. Применение ламивудина при хроническом гепатите В у детей. Детские инфекции. – 2004. - №1. – С. 30-33. 122. Рейзис А.Р. Противовирусное лечение хронического гепатита В у детей. Российский медицинский журнал 2003. Т11. № 3. С.42-46 123. Ковалев О.В., Чередниченко Т.В. Комбинированная терапия хронических вирусных гепатитов у детей. //Детские инфекции. 2003. №1.- С13-16 124. Учайкин В.Ф., Ковалев О.Б. Применение фосфоглива при острых и хронических вирусных гепатитах у детей. Детские инфекции. 2006.Том 5. №1. С 38- 43 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417–422. Vibert E., Azoulay D., Hoti E. et al. Accuracy of ultrasonography, spiral CT, magnetic resonance and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol., 2006 – № 101 (3) – P. 575-580 Трефилов А.А., Карельская Н.А., Кармазановский Г.Г. и др. Лучевая диагностика гепатоцеллюлярного рака на фоне цирроза печени. Диагностическая и интервенционная радиология. 2014; 8(2-2): С. 70 – 80. 125. Инструкция по применению препарата Вемлиди – ЛП 005643 126. Murray et al., HEPATOLOGY, Vol. 56, No. 6, 2012 127. Инструкция по применению препарата Виреад – ЛП 000779; 128. Study AI463028: Evaluation of the pharmacokinetics, safety, tolerability and efficacy of entecavir (ETV) in pediatric subjects with chronic hepatitis B virus (HBV) 85 infection who are HBeAg-positive. Week 120 clinical study report. Bristol-Myers Squibb Company; 2013. Document Control No. 930070743. 129. Study AI463189: A comparative study of the antiviral efficacy and safety of entecavir (ETV) versus placebo in pediatric subjects with chronic hepatitis B virus (HBV) infection who are HBeAg positive. Week 48 primary cohort clinical study report. Bristol-Myers Squibb Company; 2013. Document Control No. 930071188. 130. Черний В.И. Роль и место альбумина в современной инфузионнотрансфузионной терапии. Медицина неотложных состояний. 2017; 1 (80): 23-31 Haque TR, Barritt AS 4th. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):133-42. doi: 10.1016/j.bpg.2016.02.004. Epub 2016 Feb 9. PMID: 27048904. Sehgal R, Bedi O, Trehanpati N. Role of Microbiota in Pathogenesis and Management of Viral Hepatitis. Front Cell Infect Microbiol. 2020 Aug 11;10:341. doi: 10.3389/fcimb.2020.00341. PMID: 32850467; PMCID: PMC7431464. Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018 Jan;47(2):192-202. doi: 10.1111/apt.14397. Epub 2017 Oct 30. PMID: 29083037. Fox RK, Muniraj T. Pharmacologic Therapies in Gastrointestinal Diseases. Med Clin North Am. 2016 Jul;100(4):827-50. doi: 10.1016/j.mcna.2016.03.009. PMID: 27235617. Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res. 2019 Mar;3(1):3-18. doi: 10.1016/j.livres.2019.02.001. Epub 2019 Feb 20. PMID: 32461811; PMCID: PMC7251939. 131. Szajewska H., Guarino A. et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN working group for probiotics and prebiotics. JPGN2014;58: 531-539/ 132. Szajewska H., Kolodziej M., Zalewski В. M. Systematic review with metaanalysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update //Alimentary Pharmacology & Therapeutics. - 2020. - T. 51. - №. 7. - C. 678-688. 133. Odièvre M. et al. Seroimmunologic classification of chronic hepatitis in 57 children //Hepatology. – 1983. – Т. 3. – №. 3. – С. 407-409. 134. Kansu A. et al. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha //Turk J Gastroenterol. – 2004. – Т. 15. – №. 4. – С. 213-218. 135. Xu Z. et al. Assessment of liver fibrosis by transient elastography in young children with chronic hepatitis B virus infection //Hepatology international. – 2021. – Т. 15. – №. 3. – С. 602-610. 136. Sökücü S. et al. The role of the non-invasive serum marker FibroTest–ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection //Scandinavian journal of infectious diseases. – 2010. – Т. 42. – №. 9. – С. 699-703. 137. Akyuz M. et al. The evaluation of the use of 2D shear-wave ultrasound elastography in differentiation of clinically insignificant and significant liver fibrosis in pediatric age group //Abdominal Radiology. – 2021. – Т. 46. – №. 5. – С. 1941-1946. 138. Mogul D. B. et al. Characteristics of Hepatitis B virus–associated hepatocellular carcinoma in children: a multi-center study //Journal of pediatric gastroenterology and nutrition. – 2018. – Т. 67. – №. 4. – С. 437-440. 139. Chavhan G. B. et al. Gadobenate-dimeglumine-enhanced magnetic resonance imaging for hepatic lesions in children //Pediatric radiology. – 2014. – Т. 44. – №. 10. – С. 1266-1274. 86 140. Stinco M. et al. Treatment of hepatitis B virus infection in children and adolescents //World Journal of Gastroenterology. – 2021. – Т. 27. – №. 36. – С. 6053. 141. Matanina N. V., Reĭzis A. R. Peripheral blood lymphocyte apoptosis in children with viral hepatites A, B, C and effect of ursodeoxycholic acid preparations //Eksperimental'naia i Klinicheskaia Gastroenterologiia= Experimental & Clinical Gastroenterology. – 2008. – №. 5. – С. 106-110. 142. Pinto R. B., Schneider A. C. R., da Silveira T. R. Cirrhosis in children and adolescents: An overview //World journal of hepatology. – 2015. – Т. 7. – №. 3. – С. 392. 143. Применение альбумина: каковы доказательства клинического преимущества? Систематизированный обзор рандомизированных контролируемых испытаний. G.R. Haynes, R.G. Navickist, M.M.Wilkest. European Journal of Anaesthesiology.2003. 20. 771-793 144. Yachha S. K., Khanna V. Ascites in childhood liver disease //The Indian Journal of Pediatrics. – 2006. – Т. 73. – №. 9. – С. 819-824.